Elcatonin attenuates disuse osteoporosis after fracture fixation of tubular bone in rats

Journal of Orthopaedic Surgery and Research

Binshang Lan¹  Kunzheng Wang¹  Xiaoqian Dang¹  Shengli Huang¹  Chao Shi¹  Zhe Ji¹ 

[1] Department of Orthopaedics, The Second Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, People’s Republic of China

关键词: Fixation;    Bone fracture;    Disuse osteoporosis;    Elcatonin;   

Others  :  1219209
DOI  :  10.1186/s13018-015-0246-0

 received in 2015-04-27, accepted in 2015-06-26,  发布年份 2015

【 摘 要 】

Background

Elcatonin (ECT) is used to prevent and treat osteoporosis. However, little is known about its effect on the disuse osteoporosis (DOP). The aim of this study is to evaluate the effect of ECT on DOP caused by fracture fixation.

Methods

Forty-five male Sprague-Dawley (SD) rats, aged 6 weeks, were randomly allocated into three groups: the control group without surgery and elcatonin treatment (CTR, n = 15), the surgery group without elcatonin treatment (SUR, n = 15), and the surgery group which received elcatonin subcutaneously (SUR + ECT, n = 15). Surgery was produced by cutting the midshaft of the right femur transversely, fixing with stainless intramedullary needle, and immobilizing the right leg. All the proximal tibias from the random five rats in each group were harvested and investigated by evaluating bone mineral density (BMD), X-ray images, and histological staining respectively at the 4th, 8th, and 12th weeks after surgery.

Results

Both of the SUR and SUR + ECT groups obviously exhibited lower BMD values compared to the CTR group; however, the SUR + ECT group showed significantly higher BMD values (p < 0.001, p < 0.05, and p < 0.05) than the SUR group at each time point after surgery. Moreover, similar changes were observed between these groups when examining the radiographs and hematoxylin and eosin (HE) staining.

Conclusions

Elcatonin attenuates disuse osteoporosis after fractures in rats, which may provide a new avenue to prevent and treat disuse osteoporosis after surgery in clinic.

【 授权许可】

   
2015 Ji et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Alexandre C, Vico L. Pathophysiology of bone loss in disuse osteoporosis. Joint Bone Spine. 2011; 78(6):572-6.
• [2]Qi W, Yan YB, Lei W, Wu ZX, Zhang Y, Liu D et al.. Prevention of disuse osteoporosis in rats by Cordyceps sinensis extract. Osteoporos Int. 2012; 23(9):2347-57.
• [3]Takata S, Yasui N. Disuse osteoporosis. J Med Invest. 2001; 48(3–4):147-56.
• [4]Wang H, Wan Y, Tam KF, Ling S, Bai Y, Deng Y et al.. Resistive vibration exercise retards bone loss in weight-bearing skeletons during 60 days bed rest. Osteoporos Int. 2012; 23(8):2169-78.
• [5]Garland DE, Adkins RH, Stewart CA, Ashford R, Vigil D. Regional osteoporosis in women who have a complete spinal cord injury. J Bone Joint Surg Am. 2001; 83-A(8):1195-200.
• [6]Kannus P, Jarvinen M, Sievanen H, Oja P, Vuori I. Osteoporosis in men with a history of tibial fracture. J Bone Miner Res. 1994; 9(3):423-9.
• [7]Collet P, Uebelhart D, Vico L, Moro L, Hartmann D, Roth M et al.. Effects of 1- and 6-month spaceflight on bone mass and biochemistry in two humans. Bone. 1997; 20(6):547-51.
• [8]Lau RY, Guo X. A review on current osteoporosis research: with special focus on disuse bone loss. J Osteoporos. 2011; 2011:293808.
• [9]Manabe T, Mori S, Mashiba T, Cao Y, Kaji Y, Iwata K et al.. Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab. 2009; 27(3):295-302.
• [10]Katae Y, Tanaka S, Sakai A, Nagashima M, Hirasawa H, Nakamura T. Elcatonin injections suppress systemic bone resorption without affecting cortical bone regeneration after drill-hole injuries in mice. J Orthop Res. 2009; 27(12):1652-8.
• [11]Chambers TJ, Moore A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab. 1983; 57(4):819-24.
• [12]Ogawa K, Hori M, Takao R, Sakurada T. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab. 2005; 23(5):351-8.
• [13]Ito A, Kumamoto E, Takeda M, Shibata K, Sagai H, Yoshimura M. Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J Neurosci. 2000; 20(16):6302-8.
• [14]Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int. 2005; 16(10):1281-90.
• [15]Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y et al.. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab. 2005; 23(2):167-73.
• [16]Hongo M, Miyakoshi N, Kasukawa Y, Ishikawa Y, Shimada Y. Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab. 2014.
• [17]Farmer RP, Herbert B, Cuellar DO, Hao J, Stahel PF, Yasui R et al.. Osteoporosis and the orthopaedic surgeon: basic concepts for successful co-management of patients’ bone health. Int Orthop. 2014; 38(8):1731-8.
• [18]Mathavan N, Bosemark P, Isaksson H, Tagil M. Investigating the synergistic efficacy of BMP-7 and zoledronate on bone allografts using an open rat osteotomy model. Bone. 2013; 56(2):440-8.
• [19]Zarzhevsky N, Coleman R, Volpin G, Fuchs D, Stein H, Reznick AZ. Muscle recovery after immobilisation by external fixation. J Bone Joint Surg Br. 1999; 81(5):896-901.
• [20]Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984; 2(1):97-101.
• [21]Shen WW, Zhao JH. Pulsed electromagnetic fields stimulation affects BMD and local factor production of rats with disuse osteoporosis. Bioelectromagnetics. 2010; 31(2):113-9.
• [22]Iwamoto J, Takeda T, Ichimura S, Uzawa M. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study. J Orthop Sci. 2002; 7(6):637-43.
• [23]Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H. Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis. Ther Clin Risk Manag. 2009; 5(3):499-505.
• [24]Takakuwa M, Iwamoto J. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Biol Pharm Bull. 2012; 35(7):1159-65.
• [25]Wey A, Cunningham C, Hreha J, Breitbart E, Cottrell J, Ippolito J et al.. Local ZnCl2 accelerates fracture healing. J Orthop Res. 2014; 32(6):834-41.
• [26]Bouxsein ML. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin Cornerstone. 2003; Suppl 2:S13-21.
• [27]Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord. 2006; 7(1–2):75-89.
• [28]Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y et al.. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996; 137(11):4685-90.